Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the KSA.
Campus
Campus

Management of Allergic Rhinitis Aggravated by Air Pollution

Pollution is the introduction of harmful substances, or pollutants, into the environment that leads to the deterioration of the quality of air, water, and land.

The impact of air pollution on allergic symptoms is modulated by 4 factors.

Air pollutants

A mixture of solid particles, liquid droplets and gases. Air pollutants can be natural, such as bush fires, or created by human activity, such as motor vehicles.

Allergens

Biological air pollutants derive from living organisms. Some allergens are more significant indoors, while others are more important outdoors.

  • Particulate matter
    • Ultra-fine (<1 μm)
    • Fine (<1–2.5 μm)
    • Coarse (2.5–10 μm)
Diesel Exhaust
Particles (DEP)		 Ozone House dust mites Pet dander Pollen

 

Outdoor air pollution constituted more than 3% of the annual Disability-Adjusted Life Year in 2010.

 

Recommendations for patients

Avoidance

Remain indoors during high pollen levels.

 

Elimination

Eliminate sources of indoor mold
spores, clean thoroughly.
 

Treatment

Recommend 2nd generation antihistamines or
intranasal corticosteroids, anticholinergics, and
nasal lavage

Reference

  1. Naclerio R, Ansotegui IJ, Bousquet J et al. World Allergy Organ J. 2020 Mar; 13(3): 100106. Published online 2020 Apr 3. doi: 10.1016/j.waojou.2020.100106

How to create a healthy environment

Reference

  1. Naclerio R, Ansotegui IJ, Bousquet J et al. World Allergy Organ J. 2020 Mar; 13(3): 100106. Published online 2020 Apr 3. doi: 10.1016/j.waojou.2020.100106

Reference: Telfast® 180 mg film-coated tablets Patient Information leaflet ; Revision Date January 2019

Sanofi-aventis Australia pty ltd 12-24 Talavera Road Macquarie Park NSW 2113 Australia.

Disclaimer:*Fexofenadine HCl 180 mg is registered in both markets of UAE and KSA please refer to the respective Patient Information leaflet.

 

Consumer HealthCare Details:

SAUDI ARABIA:

SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318, Fax: +966-12-663-6191
For Pharmacovigilance, Please contact: +966-54-428-4797, ksa_pharmacovigilance@sanofi.com
To report any side effect(s): The National Pharmacovigilance and Drug Safety Centre (NPC) • Fax: +966-11-205-7662 SFDA call center: 19999 • E-mail: npc.drug@sfda.gov.sa • Website: https://ade.sfda.gov.sa/
To report any Product Technical Complaint, please contact SANOFI Quality Department: Email: quality.greatergulf@sanofi.com

Related articles
MAT-SA-2300121/V1/March 2023